Prescribing Doc's Testimony Key In 2nd Philly Xarelto Trial
After a $28 million verdict in a bellwether Xarelto case in Philadelphia was axed over testimony that additional warnings about the drug's bleeding risks wouldn't have changed a doctor's prescribing decision,...To view the full article, register now.
Already a subscriber? Click here to view full article